NCT05674474View on ClinicalTrials.gov

A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

March 14, 2023

Primary Completion Date

July 18, 2023

Study Completion Date

July 18, 2023

Conditions

Hepatic Impairment

Interventions

DRUG

Vorasidenib

Administered orally as tablets.

Trial Locations (1)

78215

American Research Corporation, San Antonio

All Listed Sponsors

lead

Institut de Recherches Internationales Servier

OTHER